Prisma Capital Partners LP acquired a new position in shares of Humana Inc. (NYSE:HUM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 29,600 shares of the insurance provider’s stock, valued at approximately $7,122,000. Humana accounts for 10.9% of Prisma Capital Partners LP’s holdings, making the stock its 2nd biggest holding.

A number of other institutional investors have also modified their holdings of the stock. Guardian Life Insurance Co. of America raised its stake in Humana by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares during the period. Reliance Trust Co. of Delaware raised its stake in Humana by 0.7% during the 2nd quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock worth $270,000 after buying an additional 8 shares during the period. Creative Planning raised its stake in Humana by 0.3% during the 2nd quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the period. Cadence Capital Management LLC raised its stake in Humana by 0.4% during the 2nd quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after buying an additional 22 shares during the period. Finally, Sit Investment Associates Inc. raised its stake in Humana by 0.3% during the 2nd quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after buying an additional 40 shares during the period. 95.14% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages recently commented on HUM. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Morgan Stanley raised their price objective on Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a research note on Thursday, August 17th. UBS AG reaffirmed a “neutral” rating and set a $250.00 price objective (up previously from $237.00) on shares of Humana in a research note on Wednesday, August 9th. Finally, Deutsche Bank AG raised their price objective on Humana from $234.00 to $243.00 and gave the stock a “hold” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. Humana presently has a consensus rating of “Buy” and a consensus price target of $244.35.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/prisma-capital-partners-lp-acquires-shares-of-29600-humana-inc-hum.html.

In other Humana news, insider William Kevin Fleming sold 3,071 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now directly owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP M Todoroff Christopher sold 22,935 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total transaction of $5,791,546.20. Following the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at $6,060,732.52. The disclosure for this sale can be found here. Insiders have sold 60,566 shares of company stock valued at $15,326,746 over the last three months. 0.80% of the stock is owned by corporate insiders.

Humana Inc. (NYSE:HUM) traded up 0.51% during midday trading on Monday, hitting $257.88. 253,193 shares of the stock were exchanged. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $259.76. The firm’s 50-day moving average price is $247.99 and its 200 day moving average price is $230.20. The firm has a market capitalization of $37.27 billion, a P/E ratio of 21.21 and a beta of 0.87.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the previous year, the company earned $2.30 earnings per share. Analysts expect that Humana Inc. will post $11.55 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, September 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.62%. Humana’s payout ratio is 13.06%.

Humana Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.